Endothelial Phospholipase Cγ2 Improves Outcomes of Diabetic Ischemic Limb Rescue Following VEGF Therapy

dc.contributor.authorRustagi, Yashika
dc.contributor.authorAbouhashem, Ahmed S.
dc.contributor.authorVerma, Priyanka
dc.contributor.authorVerma, Sumit S.
dc.contributor.authorHernandez, Edward
dc.contributor.authorLiu, Sheng
dc.contributor.authorKumar, Manishekhar
dc.contributor.authorGuda, Poornachander R.
dc.contributor.authorSrivastava, Rajneesh
dc.contributor.authorMohanty, Sujit K.
dc.contributor.authorKacar, Sedat
dc.contributor.authorMahajan, Sanskruti
dc.contributor.authorWanczyk, Kristen E.
dc.contributor.authorKhanna, Savita
dc.contributor.authorMurphy, Michael P.
dc.contributor.authorGordillo, Gayle M.
dc.contributor.authorRoy, Sashwati
dc.contributor.authorWan, Jun
dc.contributor.authorSen, Chandan K.
dc.contributor.authorSingh, Kanhaiya
dc.contributor.departmentMedicine, School of Medicine
dc.date.accessioned2024-01-12T10:06:29Z
dc.date.available2024-01-12T10:06:29Z
dc.date.issued2022
dc.description.abstractTherapeutic vascular endothelial growth factor (VEGF) replenishment has met with limited success for the management of critical limb-threatening ischemia. To improve outcomes of VEGF therapy, we applied single-cell RNA sequencing (scRNA-seq) technology to study the endothelial cells of the human diabetic skin. Single-cell suspensions were generated from the human skin followed by cDNA preparation using the Chromium Next GEM Single-cell 3' Kit v3.1. Using appropriate quality control measures, 36,487 cells were chosen for downstream analysis. scRNA-seq studies identified that although VEGF signaling was not significantly altered in diabetic versus nondiabetic skin, phospholipase Cγ2 (PLCγ2) was downregulated. The significance of PLCγ2 in VEGF-mediated increase in endothelial cell metabolism and function was assessed in cultured human microvascular endothelial cells. In these cells, VEGF enhanced mitochondrial function, as indicated by elevation in oxygen consumption rate and extracellular acidification rate. The VEGF-dependent increase in cell metabolism was blunted in response to PLCγ2 inhibition. Follow-up rescue studies therefore focused on understanding the significance of VEGF therapy in presence or absence of endothelial PLCγ2 in type 1 (streptozotocin-injected) and type 2 (db/db) diabetic ischemic tissue. Nonviral topical tissue nanotransfection technology (TNT) delivery of CDH5 promoter-driven PLCγ2 open reading frame promoted the rescue of hindlimb ischemia in diabetic mice. Improvement of blood flow was also associated with higher abundance of VWF+/CD31+ and VWF+/SMA+ immunohistochemical staining. TNT-based gene delivery was not associated with tissue edema, a commonly noted complication associated with proangiogenic gene therapies. Taken together, our study demonstrates that TNT-mediated delivery of endothelial PLCγ2, as part of combination gene therapy, is effective in diabetic ischemic limb rescue.
dc.eprint.versionFinal published version
dc.identifier.citationRustagi Y, Abouhashem AS, Verma P, et al. Endothelial Phospholipase Cγ2 Improves Outcomes of Diabetic Ischemic Limb Rescue Following VEGF Therapy. Diabetes. 2022;71(5):1149-1165. doi:10.2337/db21-0830
dc.identifier.urihttps://hdl.handle.net/1805/37987
dc.language.isoen_US
dc.publisherAmerican Diabetes Association
dc.relation.isversionof10.2337/db21-0830
dc.relation.journalDiabetes
dc.rightsPublisher Policy
dc.sourcePMC
dc.subjectDiabetes mellitus
dc.subjectEndothelial cells
dc.subjectPhospholipase C gamma
dc.subjectVascular endothelial growth factors
dc.subjectvon Willebrand Factor
dc.titleEndothelial Phospholipase Cγ2 Improves Outcomes of Diabetic Ischemic Limb Rescue Following VEGF Therapy
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
db210830.pdf
Size:
8.93 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: